Humanin antagonists

Mutants that interfere with dimerization inhibit neuroprotection by Humanin

Yuichi Hashimoto, Kenzo Terashita, Takako Niikura, Yohichi Yamagishi, Miho Ishizaka, Kohsuke Kanekura, Tomohiro Chiba, Marina Yamada, Yoshiko Kita, Sadakazu Aiso, Masaaki Matsuoka, Ikuo Nishimoto

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The 24-residue peptide Humanin (HN) protects neuronal cells from insults of various Alzheimer's disease (AD) genes and Aβ by forming a homodimer. We have previously shown that P3A, S7A, C8A, L9A, L12A, T13A, S14A and P19A mutations nullify the neuroprotective function of HN [Yamagishi, Y, Hashimoto, Y., Niikura, T. & Nishimoto, I. (2003) Peptides, 24, 585-595]. Here we examined whether any of these 'null' mutants could function as dominant-negative mutants. Homodimerization-defective mutants, P3A-, L12A-, S14A- and P19A-HN, specifically blocked neuroprotection by HN, but not by activity-dependent neurotrophic factor. Furthermore, insertion of S7A, the mutation that blocks the homodimerization of HN, but not insertion of G5A abolished the antagonizing function of L12A-HN. While L12A-HN and G5A/L12A-HN actually inhibited HN homodimerization, S7A/L12A-HN had no effect. These data indicate that P3A-, L12A-, S14A- and P19A-HN function as HN antagonists by forming an inactive dimer with HN. This study provides a novel insight into the understanding of the in vivo function of HN, as well as into the development of clinically applicable HN neutralizers.

Original languageEnglish
Pages (from-to)2357-2364
Number of pages8
JournalEuropean Journal of Neuroscience
Volume19
Issue number9
Publication statusPublished - 2004 May

Fingerprint

Dimerization
humanin
Neuroprotection
Peptides
Insertional Mutagenesis
Alzheimer Disease

Keywords

  • Alzheimer's disease
  • Dimerization
  • Neuronal death
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Hashimoto, Y., Terashita, K., Niikura, T., Yamagishi, Y., Ishizaka, M., Kanekura, K., ... Nishimoto, I. (2004). Humanin antagonists: Mutants that interfere with dimerization inhibit neuroprotection by Humanin. European Journal of Neuroscience, 19(9), 2357-2364.

Humanin antagonists : Mutants that interfere with dimerization inhibit neuroprotection by Humanin. / Hashimoto, Yuichi; Terashita, Kenzo; Niikura, Takako; Yamagishi, Yohichi; Ishizaka, Miho; Kanekura, Kohsuke; Chiba, Tomohiro; Yamada, Marina; Kita, Yoshiko; Aiso, Sadakazu; Matsuoka, Masaaki; Nishimoto, Ikuo.

In: European Journal of Neuroscience, Vol. 19, No. 9, 05.2004, p. 2357-2364.

Research output: Contribution to journalArticle

Hashimoto, Y, Terashita, K, Niikura, T, Yamagishi, Y, Ishizaka, M, Kanekura, K, Chiba, T, Yamada, M, Kita, Y, Aiso, S, Matsuoka, M & Nishimoto, I 2004, 'Humanin antagonists: Mutants that interfere with dimerization inhibit neuroprotection by Humanin', European Journal of Neuroscience, vol. 19, no. 9, pp. 2357-2364.
Hashimoto Y, Terashita K, Niikura T, Yamagishi Y, Ishizaka M, Kanekura K et al. Humanin antagonists: Mutants that interfere with dimerization inhibit neuroprotection by Humanin. European Journal of Neuroscience. 2004 May;19(9):2357-2364.
Hashimoto, Yuichi ; Terashita, Kenzo ; Niikura, Takako ; Yamagishi, Yohichi ; Ishizaka, Miho ; Kanekura, Kohsuke ; Chiba, Tomohiro ; Yamada, Marina ; Kita, Yoshiko ; Aiso, Sadakazu ; Matsuoka, Masaaki ; Nishimoto, Ikuo. / Humanin antagonists : Mutants that interfere with dimerization inhibit neuroprotection by Humanin. In: European Journal of Neuroscience. 2004 ; Vol. 19, No. 9. pp. 2357-2364.
@article{47850987b4354506afa7dcf527dbf5a6,
title = "Humanin antagonists: Mutants that interfere with dimerization inhibit neuroprotection by Humanin",
abstract = "The 24-residue peptide Humanin (HN) protects neuronal cells from insults of various Alzheimer's disease (AD) genes and Aβ by forming a homodimer. We have previously shown that P3A, S7A, C8A, L9A, L12A, T13A, S14A and P19A mutations nullify the neuroprotective function of HN [Yamagishi, Y, Hashimoto, Y., Niikura, T. & Nishimoto, I. (2003) Peptides, 24, 585-595]. Here we examined whether any of these 'null' mutants could function as dominant-negative mutants. Homodimerization-defective mutants, P3A-, L12A-, S14A- and P19A-HN, specifically blocked neuroprotection by HN, but not by activity-dependent neurotrophic factor. Furthermore, insertion of S7A, the mutation that blocks the homodimerization of HN, but not insertion of G5A abolished the antagonizing function of L12A-HN. While L12A-HN and G5A/L12A-HN actually inhibited HN homodimerization, S7A/L12A-HN had no effect. These data indicate that P3A-, L12A-, S14A- and P19A-HN function as HN antagonists by forming an inactive dimer with HN. This study provides a novel insight into the understanding of the in vivo function of HN, as well as into the development of clinically applicable HN neutralizers.",
keywords = "Alzheimer's disease, Dimerization, Neuronal death, Neuroprotection",
author = "Yuichi Hashimoto and Kenzo Terashita and Takako Niikura and Yohichi Yamagishi and Miho Ishizaka and Kohsuke Kanekura and Tomohiro Chiba and Marina Yamada and Yoshiko Kita and Sadakazu Aiso and Masaaki Matsuoka and Ikuo Nishimoto",
year = "2004",
month = "5",
language = "English",
volume = "19",
pages = "2357--2364",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Humanin antagonists

T2 - Mutants that interfere with dimerization inhibit neuroprotection by Humanin

AU - Hashimoto, Yuichi

AU - Terashita, Kenzo

AU - Niikura, Takako

AU - Yamagishi, Yohichi

AU - Ishizaka, Miho

AU - Kanekura, Kohsuke

AU - Chiba, Tomohiro

AU - Yamada, Marina

AU - Kita, Yoshiko

AU - Aiso, Sadakazu

AU - Matsuoka, Masaaki

AU - Nishimoto, Ikuo

PY - 2004/5

Y1 - 2004/5

N2 - The 24-residue peptide Humanin (HN) protects neuronal cells from insults of various Alzheimer's disease (AD) genes and Aβ by forming a homodimer. We have previously shown that P3A, S7A, C8A, L9A, L12A, T13A, S14A and P19A mutations nullify the neuroprotective function of HN [Yamagishi, Y, Hashimoto, Y., Niikura, T. & Nishimoto, I. (2003) Peptides, 24, 585-595]. Here we examined whether any of these 'null' mutants could function as dominant-negative mutants. Homodimerization-defective mutants, P3A-, L12A-, S14A- and P19A-HN, specifically blocked neuroprotection by HN, but not by activity-dependent neurotrophic factor. Furthermore, insertion of S7A, the mutation that blocks the homodimerization of HN, but not insertion of G5A abolished the antagonizing function of L12A-HN. While L12A-HN and G5A/L12A-HN actually inhibited HN homodimerization, S7A/L12A-HN had no effect. These data indicate that P3A-, L12A-, S14A- and P19A-HN function as HN antagonists by forming an inactive dimer with HN. This study provides a novel insight into the understanding of the in vivo function of HN, as well as into the development of clinically applicable HN neutralizers.

AB - The 24-residue peptide Humanin (HN) protects neuronal cells from insults of various Alzheimer's disease (AD) genes and Aβ by forming a homodimer. We have previously shown that P3A, S7A, C8A, L9A, L12A, T13A, S14A and P19A mutations nullify the neuroprotective function of HN [Yamagishi, Y, Hashimoto, Y., Niikura, T. & Nishimoto, I. (2003) Peptides, 24, 585-595]. Here we examined whether any of these 'null' mutants could function as dominant-negative mutants. Homodimerization-defective mutants, P3A-, L12A-, S14A- and P19A-HN, specifically blocked neuroprotection by HN, but not by activity-dependent neurotrophic factor. Furthermore, insertion of S7A, the mutation that blocks the homodimerization of HN, but not insertion of G5A abolished the antagonizing function of L12A-HN. While L12A-HN and G5A/L12A-HN actually inhibited HN homodimerization, S7A/L12A-HN had no effect. These data indicate that P3A-, L12A-, S14A- and P19A-HN function as HN antagonists by forming an inactive dimer with HN. This study provides a novel insight into the understanding of the in vivo function of HN, as well as into the development of clinically applicable HN neutralizers.

KW - Alzheimer's disease

KW - Dimerization

KW - Neuronal death

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=2942594839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942594839&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 2357

EP - 2364

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 9

ER -